Cargando…
The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence
BACKGROUND: The Costa Rican COVID-19 vaccination program has used Pfizer-BioNTech and Oxford-AstraZeneca vaccines. Real-world estimates of the effectiveness of these vaccines to prevent hospitalizations range from 90%-98% for two doses and from 70%-91% for a single dose. Almost all of these estimate...
Autor principal: | Rosero-Bixby, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128731/ https://www.ncbi.nlm.nih.gov/pubmed/35483079 http://dx.doi.org/10.2196/35054 |
Ejemplares similares
-
Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021) -
AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea
Publicado: (2021) -
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
por: Whitaker, Heather J., et al.
Publicado: (2022) -
Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
por: Phumisantiphong, Uraporn, et al.
Publicado: (2023) -
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
por: Eyre, David W., et al.
Publicado: (2021)